USA flag logo/image

An Official Website of the United States Government

A therapeutic potential of soluble decoy receptor 3 in sepsis

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
79689
Program Year/Program:
2006 / SBIR
Agency Tracking Number:
GM076828
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
BIOPOWERTECH
BIOPOWERTECH 4734 BLUEGRASS PKY TUSCALOOSA, AL 35406 4040
View profile »
Woman-Owned: Yes
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2006
Title: A therapeutic potential of soluble decoy receptor 3 in sepsis
Agency: HHS
Contract: 1R43GM076828-01
Award Amount: $112,572.00
 

Abstract:

DESCRIPTION (provided by applicant): Sepsis a serious life-threatening condition resulting from a harmful inflammatory reaction of the body due to bacterial infection. The mortality rate of sepsis remains high in intensive care units around the world but therapeutic interventions have been largely unsuccessful. Clearly, there is a great need for inventing efficacious therapeutic drugs to treat patients with sepsis associated illnesses. Increasing evidence indicates that aberrant apoptosis (programmed cell death) plays a key role in sepsis-related death but currently no drugs to prevent apoptosis in sepsis are available for clinical use. A soluble receptor protein has been demonstrated for its survival effects in animal lethality induced by apoptosis. Moreover, the level of this protein was significantly elevated in human cells in response to bacterial antigens and in sera of patients with bacterial infections thus indicating that the protein might play an important role in the pathogenesis of bacterial infection and sepsis. Therefore, we propose to accomplish two goals in this Phase I SBIR study. First, we propose to develop a high quality recombinant receptor protein so that the protein can be safe and effective for clinical use. Second, to evaluate the future therapeutic potential of the protein to treat septic patients, we propose to test whether the protein provides a survival advantage in an animal model of sepsis. Undoubtedly, our phase I SBIR studies will enhance our ability to advance to future SBIR studies designed to further evaluate the efficacy of the protein in clinical settings. If this soluble receptor protein can be effective for treating patients with sepsis, this will increase the success rate of therapy thus reducing the burden of medical care costs, as well as enhancing the quality of the patients' life

Principal Investigator:

Sunghee Kim
2053452512
sunghee_kim_bpt@yahoo.com

Business Contact:

Stavros Belbas
2053452512
S_BELBAS_BPT@YAHOO.COM
Small Business Information at Submission:

BIOPOWERTECH
BIOPOWERTECH 4734 BLUEGRASS PKY TUSCALOOSA, AL 35406

EIN/Tax ID: 260100694
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No